BankingBusiness

Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

  • Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders
  • Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid
  • The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid
  • Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund
  • The company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC)
  • Amniotics has also an, by Läkemedelsverket, approved GMP facility to produce Advanced Therapy Medicinal Products (ATMPs)
Previous article
Swift: Passes on €50 million one-time discount
Next article
Added Health: Raises Over £1M
Laura M
Laura M
Laura is a financial reporter, editor, and researcher with a particular interest in fintech innovation, capital markets, and the evolving global banking landscape.

You May Also Like

FinTech

WealthCom Secures $65M Funding Boost for Expansion

The investment aims to enhance service offerings and accelerate growth.Highlights: WealthCom raises $65 million in Series B funding.New...
FinTech

Financial Health Tools Could Unlock $5B in SME Lending

CFIT report highlights the potential of financial hygiene tools for small businesses.Highlights: CFIT report suggests financial health tools...
FinTech

Coinbase Strengthens UK Crypto Borrowing Options for Customers

Users can now borrow against their cryptocurrency holdings in the UK.Highlights: Coinbase now allows UK customers to borrow...
FinTech

Chase UK Appoints Monzo’s Malani as CEO, Strengthening Leadership Team

Former Monzo executive will lead Chase UK's growth strategy.Highlights: Chase UK appoints Monzo veteran Malani as CEO.This move...